TD Cowen began coverage on shares of Palvella Therapeutics (NASDAQ:PVLA – Free Report) in a research report released on Wednesday morning, MarketBeat.com reports. The firm issued a buy rating and a ...

TD Cowen began coverage on Palvella Therapeutics shares, assigning a Buy rating and setting a price target of $44.00. The stock, currently trading at $13.89, has already shown strong momentum with a ...

TD Cowen initiated coverage of Palvella Therapeutics (PVLA) with a Buy rating and $44 price target The firm thinks Palvella’s “promising” ...

Fintel reports that on February 5, 2025, TD Cowen initiated coverage of Palvella Therapeutics (NasdaqCM:PVLA) with a Buy ...

Palvella Therapeutics Announces First Patients Dosed in Phase 2 TOIVA Clinical Trial of QTORIN™ ... Palvella Therapeutics Inc. - (GLOBE NEWSWIRE) Jan 8, 2025 ...

Publication reports 100% of participants were either “Much Improved” or “Very Much Improved” as rated by the Clinician Global Impression of Change following 12-weeks of QTORIN™ rapamycin ...

Palvella Therapeutics (NASDAQ:PVLA – Get Free Report)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a note issued to investors on Friday,Benzinga reports.

Find the latest Palvella Therapeutics, Inc. PVLA analyst stock forecast, price target, and recommendation trends with in-depth analysis from research reports.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Neurocrine (NBIX – Research Report) and Doximity ...

Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic ...